Foundayo enjoys rapid adoption and expanding oral GLP-1 market share, with it supporting LLY's potential H2'26 outperformance against the conservative FY2026 guidance. GLP-1 therapies comprise 65.1% ...
Inventory turnover has dropped to a multi-year low. Moreover, pressure could persist per the notes I took from the FQ2 2026 actual ER due to issues like memory and substrate wafer constraints. Share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results